IgA nephropathy in a laboratory worker that progressed to end-stage renal disease: a case report
© The Author(s). 2016
Received: 30 November 2015
Accepted: 26 July 2016
Published: 8 August 2016
IgA nephropathy (IgAN) is the most common form of glomerulonephritis, a principal cause of end-stage renal disease (ESRD) worldwide. The mechanisms of onset and progression of IgAN have not been fully revealed, and epidemiologic studies have yielded diverging opinions as to the role of occupational exposure to organic solvents in the initiation or worsening of IgAN. As the authors encountered a laboratory worker with IgAN that progressed to ESRD, we present a case report of IgAN progression due to dichloromethane exposure along with a review of literature.
A 41-year-old male laboratory worker began to experience gross painless hematuria after two years of occupational exposure to toluene. Although clinical follow-up was initiated under the impression of IgAN based on clinical findings, the patient continued to work for four more years in the same laboratory, during which he was in charge of laboratory analysis with direct exposure to a high concentration of dichloromethane without proper protective equipment. During that time, his renal function rapidly worsened and finally progressed to ESRD 10 years after the first clinical symptoms. The result of exposure assessment through reenactment of his work exceeded the occupational exposure limit for dichloromethane to a considerable degree.
The causal association between occupational solvent exposure and IgAN is still unclear; therefore, this case report could be used as a basis to support the relevance of occupational solvent exposure to IgAN and/or its progression. Early intervention as well as close monitoring of laboratory workers exposed to various organic solvents is important to prevent or delay the progression of glomerulonephritis to ESRD in the occupational setting.
KeywordsIgA nephropathy End-stage renal disease Organic solvent Occupational exposure Laboratory worker Toluene Dichloromethane
IgA nephropathy (IgAN) is a glomerular disease characterized by IgA deposition in the glomerular mesangium of the kidney, which was first reported by Berger et al. in 1968 . IgAN is the most common form of glomerulonephritis in the world, accounting for about 30–45 % of all primary glomerular diseases . IgAN can occur in all age groups, but is mainly found in patients in their 10s–30s, and it is more common in males, with a male to female gender ratio of 2:1 [3, 4]. The disease can be diagnosed through biopsy by visualization of IgA deposition in the glomerular mesangial area using immunofluorescence microscopy [2, 4]. IgAN presents with macroscopic hematuria in about 40 to 45 % of patients, with microscopic hematuria and proteinuria in about 35 to 40 %, and with nephrotic syndrome or acute renal failure in the remainder [3, 5]. While IgAN has an indolent course, about 30 % of patients will reach end-stage renal disease (ESRD) after 20 years, particularly in those who present with hypertension, heavy proteinuria or renal insufficiency [3–5]. Still no treatment is known to modify mesangial deposition of IgA, and available treatment options are directed to mostly at downstream immune and inflammatory events that may lead on to renal scarring . Although the etiology and pathophysiology of IgAN have not yet been clearly identified, accumulating evidence suggests that the onset and progression are caused by interactions between various genetic and environmental factors [6–9]. Among them, occupational risk factors such as exposure to organic solvents have been suggested as probable causes that may induce [7, 8, 10] or aggravate IgAN [11–13].
The present case report is the first report in Korea suggesting the possibility that occupational exposure to organic solvents such as toluene and dichloromethane, commonly used in laboratories and industrial fields, can act as a risk factor for the onset and/or progression of IgAN. The present case report attempted to investigate the association of occupational solvent exposure and IgAN based on patient clinical information, inspection of the working environment, exposure assessment, and review of related literature, by which the authors aimed to contribute to the approach and prevention of other cases that may occur in the future.
Male, 55 years old (at the time of clinic visit for the assessment of occupational disease).
End-stage renal disease with histories of gross painless hematuria and chronic fatigue.
He first experienced the symptom of gross painless hematuria in June 2000, when he was 41 years old. Urinalysis performed in A hospital in December 2000 identified hematuria and proteinuria, while the serum creatinine (Cr) concentration was in the normal range (red blood cells [RBC]: Many, Cr: 1.3 mg/dL, 24 h urine protein: 266.2 mg/day). The patient was hired in the current laboratory institute in 1987, when he was 28 years old. Before the first episode of gross hematuria, for 2 years and 7 months (February 1998 to August 2000), corresponding to ages 39 to 41 years for the patient, his work involved analysis of the dioxin contents in exhaust gas at an incineration facility by a pretreatment method using toluene in the laboratory.
In July 2001, the patient was clinically diagnosed with IgAN without a biopsy in B hospital, and clinical follow-up was initiated. Although the patient was in follow-up after the clinical diagnosis with IgAN, he performed work involving analysis of total petroleum hydrocarbon (TPH) in soil samples using a dichloromethane as a solvent again in the laboratory for 4 years and 4 months (March 2005 to June 2009), corresponding to ages 46 to 50 years. During the TPH analysis work, the patient was continuously exposed to dichloromethane in a laboratory under conditions of poor ventilation without appropriate protective devices such as a respirator and gloves. The Cr level in the patient’s blood test started to increase from April 2006 (April 2006, Cr: 1.7 mg/dL; November 2007, Cr: 2.2 mg/dL), followed by exacerbation of the systemic fatigue symptom, so he was admitted to C hospital in March 2008, when he was 49 years old, and diagnosed with IgAN by a biopsy. Since 2008, the patient’s renal function rapidly deteriorated (June 2009, Cr 3.9 mg/dL; September 2009, Cr 5.9 mg/dL; April 2010, Cr 8.4 mg/dL) and finally progressed to ESRD, and peritoneal dialysis was begun in June 2010 when he was 51 years old. As of December 2014, he was in follow-up after kidney transplantation at the age of 55 years, after 13 years had passed from the initial clinical diagnosis with IgAN.
Clinical therapeutic course
The patient began to take an angiotensin II receptor blocker (ARB) after clinical diagnosis in 2001, and thereafter, the patient’s blood pressure, serum BUN/Cr level, and urine protein/creatinine ratio (PCR) have been measured at regular outpatient follow-ups. He incorporated life style modifications for weight management and abstained from alcohol, and started a low-salt, low-protein diet with the initiation of medication. When his serum Cr increased to 1.7 mg/dL in April 2006, he began taking an angiotensin-converting enzyme inhibitor (ACEi), HMG-CoA reductase inhibitor (statin), omega-3, and blood pressure medication, and his blood pressure, renal function, and proteinuria level were closely monitored. However, the patient’s renal function and proteinuria level began to deteriorate in 2008, and he ceased analytic work in the lab and changed to a desk job in June 2009. Despite starting oral steroid therapy in September 2009, no particular benefit was observed, and the patient began peritoneal dialysis in June 2010, eventually undergoing renal transplantation in December 2014.
The patient had a history of diagnosis at the age of 21 with pleural effusion and tuberculous pleurisy, which was completely cured after a two-year course of medication. Other than that, his past medical history is essentially unremarkable. There is no evidence of preexisting hypertension, cardiovascular disease, diabetes mellitus, and there is no preexisting history of drug abuse, alcoholism or medication abuse. The patient received regular occupational health examinations two times (in 1997 and 1999) before the onset of his first symptom of hematuria and had no abnormal findings on the corresponding health examinations, in particular, on kidney-related examinations such as hematuria and proteinuria.
His family history is essentially unremarkable. When the family history of the patient was thoroughly examined, no first-degree relatives had any history of specific disease including kidney disease.
The patient was not smoking and his alcohol intake history was 3–4 times a month, with about 0.5 bottle of soju each time.
Eight years after the first clinical symptom appeared, the patient was finally confirmed to have IgAN (subclass V, by Haas histological classification ) through a kidney biopsy, in March 2008 when he was 49 years of age. The biopsy findings were as follows: “Tubules reveal focal moderate atrophy or loss with focal moderate infiltration of mononuclear cells and fibrosis in interstitium. Fibrointimal thickening of small arteries is noted.”
Lab test follow-up
The patient’s history of occupational exposure to organic solvents with disease progression
Feb 1998 to Aug 2000
Jun 2000: Hematuria onset
Jul 2001: Clinical diagnosis of IgAN
Jul 2001: Clinical follow-up starts
Mar 2005 to Jun 2009
Oct 2006: Renal function exacerbation
Mar 2008: Renal biopsy confirmed
Jun 2010: Peritoneal dialysis starts
Dec 2014: Kidney transplantation
Among these tasks, according to our preliminary study, TPH analysis work using dichloromethane was suspected as the work in which the patient was exposed to organic solvents in a high concentration for a long period of time without proper protective devices; considering whether the presence of relevant data and the possibility of reconstruction of working environment, the present case report was focused on the TPH analysis work in detail for evaluation of occupational exposure, during which the patient’s IgAN rapidly progressed to ESRD.
The authors investigated the work environment of the laboratory institute and reviewed all past work environment data measurements. Pretreatment process in TPH analysis was performed in ‘Room A’ before 2008, where the door always remained closed during experiments due to the noise generated in the pretreatment process. According to the descriptions by the patient and coworkers, a local ventilation system had been installed for ventilation, but ventilation conditions were poor and workers often performed pretreatment works without the provision of protective devices such as a respirator and gloves. The location for pretreatment work of TPH analysis was changed in 2008 to ‘Room B’ (123.8 m2) with an area about 4 times larger than ‘Room A’ (30.1 m2). In addition to a preexisting ventilation system in ‘Room B’, an additional local ventilation system was installed in 2010, and three ultrasound-assisted extractors (the major source of dichloromethane) were placed in the newly installed hood facilities.
Exposure assessment history of the corresponding workplace for pretreatment work
Measurement result (ppm)
Mixed organic compounds
Exposure assessment through reenactment
Results of exposure reenactment of dichloromethane
Short-term exposure concentration (ppm)
Time-weighted average concentration (ppm)
A. Ultrasound-assisted extractor 1 (Respiratory location)
B. Ultrasound-assisted extractor 2 (Respiratory location)
C. Above the ultrasound-assisted extractors
These results suggest that the actual respiratory exposure concentrations of the patient to dichloromethane in ‘Room A’ during the pretreatment work for TPH analysis during the period of March 2005 to June 2009 should have been higher than the time-weighted average (50 ppm) set by the Korean Industrial Safety and Health Act and the short-term exposure limit (125 ppm) set by OSHA (Occupational Safety and Health Administration). Therefore, it can be surmised that the patient had been regularly exposed to a high concentration of dichloromethane in ‘Room A’ for 52 months.
A number of studies have reported kidney toxicity of organic solvents and an association with glomerulonephritis. Miller et al.  reported a case of acute tubular necrosis accompanied by acute renal failure, myoglobinuria, and liver enzyme elevations that were caused by inhalation exposure to dichloromethane. They conclude that dichloromethane may have potential as both a hepatotoxic and nephrotoxic agent when inhaled at high concentrations over an extended period of time . Ana-Lilia et al.  reported that shoe-workers who were occupationally exposed to toluene-based glues had a higher risk of renal glomerular and/or tubular damage than the control group. Ravnskov et al.  conducted a meta-analysis of 14 case–control studies and reported that the combined data support the hypothesis that hydrocarbon exposure increases the risk of chronic renal disease, although no specific hydrocarbons were identified in these reviews. In addition, there have also been other case reports , epidemiological studies [8, 19, 20] and animal-experimental studies [19, 21] reporting associations between solvent exposure and onset of glomerulonephritis or deterioration of renal function. On the other hand, a few studies [22, 23] reported negative results on the association between solvent exposure and the risk of chronic glomerulonephritis.
Case reports of IgAN associated with occupational solvents exposure
Gender/Age at diagnosis
Type of solvent
Albrecht et al.  (1987)
A plumber, working with solvent-based pipe cement
9 years and 6 months
Fernandez et al.  (2010)
A pesticide manufacturer
various organic solvents (toluene, xylene, acetone, cyclohexanone, etc.)
progression to CRF in 2 years after diagnosis
Meanwhile, Fernandez et al.  introduced a case of IgAN in a 50-year-old male who was exposed to various types of organic solvents for 23 years. The male was continuously exposed to organic solvents occupationally for an additional two years even after diagnosis with IgAN, resulting in progression to CRF stage 3 in two years after diagnosis with IgAN .
Epidemiological studies investigating the association of occupational solvent exposure and IgAN
Population Total GNa/IgAN
Porro et al.  (1992)
60 biopsy-proven chronic GNa patients in a University hospital in Italy (including 27 IgAN patients)
onset of IgAN
·An increased risk of IgAN was found for occupational solvent exposure group.
·RRb of IgAN for occupational solvent exposure ; 4.25 (1.18–16.36)
Stengel et al.  (1995)
298 biopsy-proven GNa patients in 5 hospitals in Paris (including 116 IgAN patients)
aggravation of IgAN to CRF
·Among males, clear association was observed between CRF and high exposure to solvents for IgAN; ORc = 3.5 (1.0–11.8), P < 0.05.
·The OR increased with duration of exposure; OR = 5.6 (1.3–24.1) for ≥10 years exposure, (P = 0.02).
·No relationship was observed for cases without CRF.
Wakai et al.  (1999)
94 biopsy-proven IgAN patients in medical centers in Japan
onset of IgAN
· Work-related exposure to organic solvents was found not to be associated with the risk for IgAN; OR = 0.55 (0.27–1.12), (P < 0.10)
Jacob et al.  (2007)
retrospective cohort study
338 non-ESRD patients in Paris (including 194 IgAN patients with biopsy confirm)
aggravation of IgAN to ESRD
·Solvent exposure was associated with faster progression of IgAN to ESRD, HRd for IgAN is 2.6 (1.3–5.5) for high exposure versus none (p < 0.05).
·There was a trend increasing HR with exposure duration before and its persistence after diagnosis.
Jacob et al.  (2007)
retrospective cohort study
269 patients with non-ESRD and biopsy-proven primary GNa diagnosis between 1994 and 2001 in Paris and suburbs (including 167 IgAN patients)
aggravation of IgAN to ESRD
·This study showed the potential role of toluene and xylene, some petroleum products, ketones and possibly dichloromethane in the progression of GNa to ESRD.
In contrast, a case–control study that was conducted by Wakai et al.  with Japanese subjects to investigate a correlation between diagnosis of IgAN and occupational exposure to organic solvents showed an odds ratio of 0.55 (95 % CI 0.27–1.12), which was not statistically significant . The authors commented that they might have failed to find a positive association because of the few number of patients with advanced renal failure, and also pointed out that another possible limitation was the methodological difficulty of measuring exposure to organic solvent .
Meanwhile, Stengel et al.  performed a case–control study to investigate a correlation between organic solvent exposure and CRF with 116 IgAN patients in five hospitals in Paris. As a result, among males, a clear association was observed between CRF and high exposure to organic solvents for IgAN patients (OR = 3.5, 95 % CI 1.0–11.8) . In addition, the odds ratio increased with duration of exposure . On the other hand, patients with IgAN who had normal renal function showed no correlation with organic solvents, so these results were interpreted to suggest that organic solvents contributed to deterioration of renal function to some degree rather than to the diagnosis itself of IgAN .
Meanwhile, in 2007, Jacob et al.  conducted the GN-PROGRESS cohort study; the authors investigated occupational risk factors for the progression of glomerulonephritis to ESRD. Using a cohort study design, they showed that solvent exposure was indeed associated with faster progression to ESRD with IgAN (Hazard ratio [HR] = 2.6, 95 % CI 1.3–5.5) . In patients with IgAN, there was a trend in increased hazard ratios with exposure duration before and its persistence after diagnosis .
In a subsequent study, using data from the GN-PROGRESS cohort, Jacob et al.  therefore systematically investigated the risk of progression to ESRD, by solvent-exposed job category, type of solvent-containing products, and by solvent or solvent family. In this analysis , they focused on the 269 patients with either IgAN or membranous nephropathy. Among solvents, the highest risks were found for: toluene/xylene (HR = 5.1, 95 CI 1.8–14.8), gasoline, fuel and gas-oil (HR = 8.6, 95 CI 2.7–27.4), and ketones (HR = 13.3, 95 % CI 1.4–123.5). Most interestingly, they also observed an excess risk for any exposure level to methylene chloride, also known as dichloromethane (HR = 6.4, 95 % CI 1.7–24.8) . In another occupational cohort study in US aircraft workers, Radican et al.  pointed to the risk of all-cause ESRD associated with trichloroethylene, 1,1,1-trichlorethane, dichloromethane, and JP4 gasoline.
In summary, regarding the relationship between occupational solvent exposure and IgAN in the literature, all reviewed studies [11, 12] consistently reported significant correlations at least between solvent exposure and the progression of preexisting IgAN to CRF or to ESRD, though study results regarding the onset of IgAN [10, 11, 29] were inconsistent (Table 5). In particular, recent cohort study results [12, 13, 30], showing the potential role of toluene and dichloromethane in the progression of IgAN to ESRD supports our hypothesis that the IgAN of this case report may have progressed more rapidly to ESRD due to occupational solvent exposure.
Although it can occur at any age, IgAN mainly occurs in young adults (16–35 years old) [3, 31–33]. In a Chinese cohort study of 1,115 patients with IgAN , the mean age at time of initial clinical manifestations and renal biopsy were 31 ± 9, and 33 ± 9 years old, respectively. For the patient in the present case, gross hematuria was first experienced at 41 years of age in June 2000, and the serum Cr level at that time was 1.3 mg/dL, corresponding to a normal level. In July 2001, he was given a clinical diagnosis of IgAN (not biopsy confirmed), which was when the patient was 42 years old. This is much older than the usual age for initial clinical presentation and diagnosis of IgAN compared to the mean age of diagnosis (10–30 years) reported in other studies [31, 32, 34], so it was suspected that this case could be different from the general cases that were diagnosed at earlier ages, at about 10–30 years, mostly due to internal or genetic factors.
For the natural history of IgAN, the actuarial renal survival rate for 10 years after diagnosis or after a biopsy is a significant parameter for prognosis prediction of IgAN [31, 35]. According to a meta-analysis by Coppo , the actuarial renal survival rate for 10 years after diagnosis with IgAN or after a biopsy was mostly about 80–90 % in Europe, Asia and Australia. Another study conducted in United Kingdom, using Medical Research Council’s Glomerulonephritis Registry , reported that the 10-year cumulative renal survival rate was 83.3 %. Le et al.  reported a cohort study with 1,115 IgAN patients in China, in which renal survival rates after diagnosis with IgAN were 83 at 10 years, 74 at 20 years, and 64 % at 30 years. In contrast to the actuarial renal survival rate of 80–90 % for 10 years reported in the literature [31, 34–36], this patient experienced rapid deterioration of renal function within only 9 years from the initial clinical diagnosis to dialysis. Thus, the prognosis is extraordinarily poor.
On the other hand, studies on factors enabling prediction of the prognosis of IgAN commonly suggested “unfavorable histopathologic findings” such as glomerular sclerosis and interstitial fibrosis, and “severe proteinuria at presentation,” “arterial hypertension at presentation and during follow-up,” and “elevated serum creatinine at presentation” as strong clinical predictors [31, 37–39]. The patient in this case did not have confirmation by biopsy until 8 years after the first onset of symptoms. Since biopsy was performed when histological damages had already progressed significantly, it is difficult to predict the prognosis based on the time points of first onset and first diagnosis based on biopsy findings. Meanwhile, this patient had a serum Cr level of 1.3 mg/dL at the time of initial clinical diagnosis, corresponding to within the normal range, and 266 mg/day of 24 h urine protein, showing that he was not in a severe condition. Furthermore, the patient had neither underlying diseases such as hypertension and diabetes from the past, nor hypertension at the time of diagnosis. In other words, although the patient was in a condition without known strong clinical predictors, the deterioration of his renal function rapidly progressed, unlike the natural progression reported in other studies [31, 34, 36]. In addition, this decline of renal function overlapped with the patient’s period of exposure to dichloromethane between March 2005 and June 2009 (Fig. 1).
In summary, based on a literature review of the natural history of IgAN, the present case has unusual clinical characteristics such as the age of disease onset, speed of progression, and the prognostic pattern. The authors surmised that the unusual characteristics of this IgAN case provide supporting evidence for the relevance of occupational solvent exposure with IgAN and/or its progression.
This case study has several limitations. First, exposure assessment for toluene could not be conducted because there were almost no relevant data remains. The first episode of hematuria, the initial clinical manifestation of IgAN in this patient, actually began after he had been exposed to toluene while performing analysis of dioxin contents in exhaust gas from an incineration facility during a period of 2 years and 7 months (Table 1). According to reports by the patient and co-workers, however, there was no proper ventilator system in the pretreatment room at that time, and workers usually did not wear protective equipment. Thus, it is presumed that there was direct exposure to a high concentration of toluene. Therefore, the authors cautiously suggest that possibilities of a causal relationship between toluene exposure and the onset and/or aggravation of IgAN could not be ruled out in present case. Secondly, despite the attempt to minimize errors by restoration of the past actual working environment at the site of investigation for exposure, there may still be errors in perfect reflection of the past working environment for the patient including ventilation conditions and the circulation of worker’s traffic. Thirdly, the health effects of other chemical substances used in the laboratory where the patient worked, or potential secondary health effects generated while various chemicals were used in combination with organic solvents, were not evaluated. In addition, another drawback in this case report is that biological monitoring markers for dichloromethane such as blood levels of carboxyhemoglobin (COHb) or urinary dichloromethane [40, 41] were not evaluated in the exposure assessment.
This case report suggests that many laboratory workers may be exposed to high levels of various hazardous chemicals including organic solvents. Although the results are controversial, several previous studies have suggested an association between occupational solvent exposure and the onset of IgAN and/or its progression to ESRD; thus, the IgAN and following ESRD in this patient might have been influenced by prolonged, high exposure to organic solvents. Because IgAN is a major cause of ESRD and there is no disease-targeted treatment, close monitoring to encourage screening for proteinuria, hematuria, or hypertension in workers exposed to organic solvents is crucial for early detection of those with a risk for IgAN. Furthermore, early intervention and elimination of exposure in those diagnosed with glomerulonephritis at an early stage may prevent or delay the progression to ESRD in these workers.
BUN, blood urea nitrogen; CI, confidence interval; Cr, creatinine; CRF, chronic renal failure; ESRD, end-stage renal disease; GN, glomerulonephritis; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-Coenzyme A; HR, hazard ratio; IgAN, IgA nephropathy; NIOSH, National Institute of Occupational Safety & Health; OEL, occupational exposure limit; OR, odds ratio; OSHA, Occupational Safety and Health Administration; PVC, polyvinyl chloride; RBC, red blood cells; RR, relative risk; STEL, short-term exposure limit;THF, tetrahydrofuran; TPH, total petroleum hydrocarbon; TWA, time-weighted average
BM collected and interpreted the data, conducted reproduction of relevant tasks, prepared the draft of this manuscript, and approved the final version of the manuscript. GK collected and interpreted the data, helped to draft this manuscript, and approved the final version of the manuscript. TK investigated the working environment, conducted reproduction of relevant tasks, assessed exposure status of workplace including sample analysis, and approved the final version of the manuscript. CSY suggested the design of this research, investigated the working environment, conducted reproduction of relevant tasks, assessed exposure status of workplace including sample analysis, and approved the final version of the manuscript. SIC suggested the design of this research, interpreted results, revised the draft of this manuscript, and approved the final version of the manuscript. DP designed this research, collected and interpreted the data, interpreted the results, and approved the final version of the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of written consent is available for review by the Editor-in-Chief of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris). 1968;74(9):694–5.Google Scholar
- Yu HH, Chiang BL. Diagnosis and classification of IgA nephropathy. Autoimmun Rev. 2014;13(4–5):556–9.View ArticlePubMedGoogle Scholar
- Galla JH. IgA nephropathy. Kidney Int. 1995;47(2):377–87.View ArticlePubMedGoogle Scholar
- Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16(7):2088–97.View ArticlePubMedGoogle Scholar
- Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol. 2000;11(12):2395–403.PubMedGoogle Scholar
- Suzuki H, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795–803.View ArticlePubMedPubMed CentralGoogle Scholar
- Lauwerys R, et al. Kidney disorders and hematotoxicity from organic solvent exposure. Scand J Work Environ Health. 1985;11 Suppl 1:83–90.PubMedGoogle Scholar
- Brautbar N. Industrial solvents and kidney disease. Int J Occup Environ Health. 2004;10(1):79–83.View ArticlePubMedGoogle Scholar
- Emancipator S. Immunoregulatory factors in the pathogenesis of IgA nephropathy. Kidney Int. 1990;38(6):1216–29.View ArticlePubMedGoogle Scholar
- Porro A, et al. Chronic glomerulonephritis and exposure to solvents: a case-referent study. Br J Ind Med. 1992;49(10):738–42.PubMedPubMed CentralGoogle Scholar
- Stengel B, et al. Glomerular nephropathies and exposure to organic solvents, a case–control study. Bull Acad Natl Med. 1996;180(4):871–9. discussion 879–83.PubMedGoogle Scholar
- Jacob S, et al. Effect of organic solvent exposure on chronic kidney disease progression: the GN-PROGRESS cohort study. J Am Soc Nephrol. 2007;18(1):274–81.View ArticlePubMedGoogle Scholar
- Jacob S, et al. New insight into solvent-related end-stage renal disease: occupations, products and types of solvents at risk. Occup Environ Med. 2007;64(12):843–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829–42.View ArticlePubMedGoogle Scholar
- Miller L, et al. Acute tubular necrosis after inhalation exposure to methylene chloride: Report of a case. Arch Intern Med. 1985;145(1):145–6.View ArticlePubMedGoogle Scholar
- Ana-Lilia G-Y, et al. Occupational exposure to toluene and its possible causative role in renal damage development in shoe workers. Int Arch Occup Environ Health. 2006;79(3):259–64.View ArticleGoogle Scholar
- Ravnskov U. Hydrocarbons may worsen renal function in glomerulonephritis: a meta-analysis of the case–control studies. Am J Ind Med. 2000;37(6):599–606.View ArticlePubMedGoogle Scholar
- Churchill D, Fine A, Gault M. Association between hydrocarbon exposure and glomerulonephritis. An appraisal of the evidence. Nephron. 1983;33(3):169–72.View ArticlePubMedGoogle Scholar
- Ravnskov U. Hydrocarbon exposure may cause glomerulonephritis and worsen renal function: evidence based on Hill’s criteria for causality. QJM. 2000;93(8):551–6.View ArticlePubMedGoogle Scholar
- Yaqoob M, et al. Primary glomerulonephritis and hydrocarbon exposure: a case–control study and literature review. QJM. 1992;83(2):409–18.PubMedGoogle Scholar
- Ravnskov U. Experimental glomerulonephritis induced by hydrocarbon exposure: a systematic review. BMC Nephrol. 2005;6(1):15.View ArticlePubMedPubMed CentralGoogle Scholar
- Fored CM, et al. Absence of association between organic solvent exposure and risk of chronic renal failure: a nationwide population-based case–control study. J Am Soc Nephrol. 2004;15(1):180–6.View ArticlePubMedGoogle Scholar
- Asal NR, et al. Hydrocarbon exposure and chronic renal disease. Int Arch Occup Environ Health. 1996;68(4):229–35.View ArticlePubMedGoogle Scholar
- Fernández J, et al. Follow-up of two patients with mesangial IgA glomerulonephritis exposed to cadmium and organic solvents. In: Anales del sistema sanitario de Navarra. 2009.Google Scholar
- Albrecht WN, Boiano JM, Smith RD. IgA glomerulonephritis in a plumber working with solvent-based pipe cement. Ind Health. 1987;25(3):157–8.View ArticlePubMedGoogle Scholar
- Nogué S, et al. Chronic overexposure to cadmium fumes associated with IgA mesangial glomerulonephritis. Occup Med. 2004;54(4):265–7.View ArticleGoogle Scholar
- Qin H, Zhang J, Xu Q. A case of IgA nephropathy union protein in workers after getting rid of exposure to cadmium. Chinese journal of industrial hygiene and occupational diseases. 2010;28(12):947.PubMedGoogle Scholar
- Fujii Y, et al. A case of IgA nephropathy associated with silicosis. Nihon Jinzo Gakkai shi. 2001;43(7):613–8.PubMedGoogle Scholar
- Wakai K, et al. Risk factors for IgA nephropathy: a case–control study in Japan. Am J Kidney Dis. 1999;33(4):738–45.View ArticlePubMedGoogle Scholar
- Radican L, et al. A retrospective occupational cohort study of end-stage renal disease in aircraft workers exposed to trichloroethylene and other hydrocarbons. Journal of occupational and environmental medicine/American College of Occupational and Environmental Medicine. 2006;48(1):1.View ArticlePubMedPubMed CentralGoogle Scholar
- D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. IgA Nephropathy. 2004;24(3):179-196. Google Scholar
- Geddes CC, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18(8):1541–8.View ArticlePubMedGoogle Scholar
- Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89(2):209–15.View ArticlePubMedGoogle Scholar
- Le W, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479–85.View ArticlePubMedGoogle Scholar
- Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503–12.PubMedGoogle Scholar
- Johnston PA, et al. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry. Q J Med. 1992;84(304):619–27.PubMedGoogle Scholar
- Xie J, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7(6):e38904.View ArticlePubMedPubMed CentralGoogle Scholar
- Berthoux F, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):752–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Radford M, et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8(2):199–207.PubMedGoogle Scholar
- Bonfiglioli R, et al. Bilateral hearing loss after dichloromethane poisoning: a case report. Am J Ind Med. 2014;57(2):254–7.View ArticlePubMedGoogle Scholar
- Sakai T, Morita Y, Wakui C. Biological monitoring of workers exposed to dichloromethane, using head-space gas chromatography. J Chromatogr B. 2002;778(1):245–50.View ArticleGoogle Scholar